Skip to contentE
Enveric Biosciences, Inc.
E
ENVBEnveric Biosciences, Inc. Q4 2018 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$10.28M$10.28Mderived−10.2% vs Q4 2017 Net Income-$19.77M-$19.77MderivedN/M vs Q4 2017 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Enveric Biosciences, Inc. · CIK 890821 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$1,905,822−6.6% Operating Incomederived-$10,935,174N/M Operating Cash Flowderived-$1,002,980N/M Margins · derivedGross margin18.5%+0.7 pt vs Q4 2017
Operating margin-106.3%−72.4 pt vs Q4 2017
Net margin-192.2%−187.7 pt vs Q4 2017
ended Dec 31, 2018 · filed Mar 26, 2019 · 85 d after period end